Advertisement

OPRX

OptimizeRx Corporation

Healthcare · USD

Set alert

Price alert · OPRX

All alert types
9.32 USD -0.05 -0.53%
As of Oct 30, 2026 Extended hours 9.20 -1.29%
Bid
9.25 × 2
Ask
9.32 × 2
9.03 Day range 9.36
4.54 52-week range 20.49
YTD
-23.98%
1 year
-52.47%
Open
9.25
Prev close
9.37
Mkt cap
175.55M
Vol
136.55K
Avg vol
182.57K
EPS
0.24
P/E
38.83
Div yield
0.00%
More statistics
Low
9.03
High
9.36
Forward P/E
9.86
Beta
0.00
Short ratio
2.70
Inst. own
68.94%
Dividend
0.00
Ex-div date
50-d avg
5.40
200-d avg
8.91
1y target
10.36

2Y chart

Chart tools
Interval
OPRX two-year price chart3.788.4013.017.622.3Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
88.97M
Enterprise value
118.13M
Trailing P/E
0.00
Forward P/E
9.86
PEG ratio
0.00
Price / sales
1.01
Price / book
0.85
EPS (TTM)
-1.34
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-27.41%
Revenue (TTM)
88.18M
Revenue growth
30.50%
Free cash flow
8.35M
Total cash
16.13M
Total debt
35.72M
Return on equity
-20.97%
Shares outstanding
18.42M
Short % of float
5.68%
50-day average
5.40
200-day average
8.91

Analyst view

Consensus: buy

Buy
Price target (mean) 10.36 +11.1% upside
Target (low)
5.50
Target (mean)
10.36
Target (high)
17.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
  • Strong buy3
  • Buy4
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate 0.25.

Earnings history

Financials — quick view

All financials
OPRX Revenue — quarterly 20.50M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
OPRX Net income — quarterly -703.00K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
OPRX EPS — quarterly -0.04
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

OPRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 20240.060.12+0.06+100.00%
Aug 8, 2024Jun 1, 2024-0.070.02+0.09+128.57%
May 14, 2024Mar 1, 2024-0.11-0.110.000.00%
Apr 16, 2024Dec 1, 20230.000.26——
Nov 6, 2023Sep 1, 20230.020.09+0.07+350.00%
Aug 14, 2023Jun 1, 2023-0.02-0.01+0.01+50.00%

Upgrades / downgrades

OPRX analyst upgrades and downgrades
DateFirmActionFromTo
Dec 20, 2024Stephens & Co.init—Equal-Weight
Nov 14, 2024RBC CapitalmainOutperformOutperform
Nov 14, 2024Roth MKMreitBuyBuy
Nov 14, 2024StifelmainBuyBuy
Nov 14, 2024BarclaysmainEqual-WeightEqual-Weight
Nov 14, 2024JMP SecuritiesmainMarket OutperformMarket Outperform

About OptimizeRx Corporation

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

Sector
Healthcare
Industry
Health Information Services
Country
United States

News

Your note

Sign in to keep a note on OPRX — it syncs with the Stock Master app.

Insider holders

OPRX insider holders
InsiderRelationLatest transactionDateShares held
BESCH DOUGOfficerConversion of Exercise of derivative securityDec 18, 202411,583
FEBBO WILLIAM JChief Executive OfficerPurchaseDec 11, 2024601,253
KLEMA CATHERINE MDirectorStock Award(Grant)Jun 6, 20246,643
LANG JAMES PAULDirectorStock Award(Grant)Jun 6, 202468,044
ODENCE-FORD MARION K.General CounselConversion of Exercise of derivative securityDec 18, 202427,230
SILVESTRO STEPHEN LOfficerConversion of Exercise of derivative securityDec 18, 202480,848

Institution ownership

OPRX institution ownership
Holder% heldSharesValueReported
First Light Asset Management, LLC14.98%1,811,6118.75MSep 29, 2024
Blackrock Inc.10.54%1,274,7616.16MSep 29, 2024
AWM Investment Company, Inc.8.86%1,071,8325.18MSep 29, 2024
Samjo Management, LLC8.64%1,044,8005.05MSep 29, 2024
Vanguard Group Inc7.88%952,8934.60MSep 29, 2024
Blair (William) & Company, L.L.C.5.60%677,0943.27MSep 29, 2024

Fund ownership

OPRX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund4.19%506,6912.45MSep 29, 2024
iShares Russell 2000 ETF3.75%453,8482.19MOct 30, 2024
Jacob Internet Fund2.30%278,2751.34MOct 30, 2024
Vanguard Extended Market Index Fund2.23%270,2681.31MSep 29, 2024
Fidelity Small Cap Index Fund1.51%182,433881.15KAug 30, 2024
iShares Russell 2000 Growth ETF1.29%156,029753.62KOct 30, 2024
Advertisement